Clinical Trials

Numerous clinical trials evaluate idarubicin across various hematologic malignancies, predominantly acute myeloid leukemia, myelodysplastic syndromes, acute lymphocytic leukemia, and B-cell lymphoma. Spanning Early Phase 1 through Phase 4, these studies are supported by academic and industry sponsors to evaluate idarubicin in combination regimens as well as in relapsed or refractory settings. Recruitment statuses across this body of research vary widely, with protocols currently listed as recruiting, active, completed, terminated, or withdrawn.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03013998 RECRUITING
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Beat AML, LLC
 2016-11 PHASE2; PHASE3
NCT07604233 NOT_YET_RECRUITING
Myeloid Leukemia
M.D. Anderson Cancer Center
 2026-11-30 PHASE1; PHASE2
NCT06482801 RECRUITING
Liver Cancer; Antibody
Second Affiliated Hospital of Guangzhou Medical University
 2024-06-10 PHASE2
NCT07232134 RECRUITING
AML (Acute Myelogenous Leukemia); Down Syndrome (DS)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
 2025-07-24 PHASE3
NCT07223814 RECRUITING
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland
 2026-03-01 PHASE3
NCT07078591 RECRUITING
Acute Myeloid Leukemia
Beijing 302 Hospital
 2025-06-20 PHASE2
NCT02115295 RECRUITING
Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Blasts 10 Percent or More of Peripheral Blood White Cells; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
M.D. Anderson Cancer Center
 2014-05-19 PHASE2
NCT04953780 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia
West Virginia University
 2021-09-27 PHASE1
NCT07228273 RECRUITING
Acute Myeloid Leukemia; Myelodysplastic Syndrome
OHSU Knight Cancer Institute
 2025-12-12 PHASE2
NCT07766850 NOT_YET_RECRUITING
R/R AML
Christer C Nilsson
 2026-10 PHASE1; PHASE2
NCT03591510 ACTIVE_NOT_RECRUITING
FLT3-mutated Acute Myeloid Leukemia
Novartis Pharmaceuticals
 2019-03-13 PHASE2
NCT07407140 NOT_YET_RECRUITING
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China
 2026-04-30 PHASE3
NCT06492421 RECRUITING
Lung Cancer; Surgery; Non-small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
 2024-07-01 PHASE2
NCT06483347 RECRUITING
Lung Cancer; Inoperable Disease
Second Affiliated Hospital of Guangzhou Medical University
 2024-04-04 PHASE2
NCT06492408 RECRUITING
Hepatic Cancer; Surgery
Second Affiliated Hospital of Guangzhou Medical University
 2024-07-01 PHASE2
NCT06221683 RECRUITING
AML, Childhood; Acute Myeloid Leukemia
Children's Hospital of Soochow University
 2024-01-01 PHASE2
NCT00801489 RECRUITING
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; de Novo Myelodysplastic Syndrome; High Risk Myelodysplastic Syndrome; Inv(16); Myelodysplastic Syndrome With Excess Blasts; t(16;16); t(8;21); Untreated Adult Acute Myeloid Leukemia
M.D. Anderson Cancer Center
 2007-04-04 PHASE2
NCT07059975 RECRUITING
Acute Myeloid Leukemia; Pediatric AML
Baylor College of Medicine
 2025-10-22 EARLY_PHASE1
NCT05749276 RECRUITING
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
Nantes University Hospital
 2025-02-06 PHASE1
NCT05260528 RECRUITING
Acute Myeloid Leukemia
Centre Hospitalier Universitaire de Nice
 2023-05-03 PHASE2
NCT06667973 NOT_YET_RECRUITING
Acute Myeloid Leukemia; FLT3 Gene Mutation; Adult AML; Diagnosis
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2025-06 PHASE2
NCT07131059 RECRUITING
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China
 2024-05-11
NCT07514832 RECRUITING
AML (Acute Myeloid Leukemia)
Beijing 302 Hospital
 2026-04-15 PHASE2
NCT06928662 RECRUITING
Acute Myeloid Leukemia; Acute Undifferentiated Leukemia; Mixed Phenotype Acute Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Acute Undifferentiated Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Mixed Phenotype Acute Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Acute Undifferentiated Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
 2025-09-23 PHASE1; PHASE2
NCT06265545 RECRUITING
AML; Refractory; Relapsed
Institute of Hematology & Blood Diseases Hospital, China
 2024-02-22
NCT03589729 RECRUITING
Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Myeloid Sarcoma; Myeloproliferative Neoplasm; Philadelphia Chromosome Positive
M.D. Anderson Cancer Center
 2018-09-19 PHASE2
NCT04047641 RECRUITING
Acute Myeloid Leukemia; Blasts 20 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
 2019-10-22 PHASE1; PHASE2
NCT06232694 RECRUITING
Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
 2024-01-01
NCT06744556 ACTIVE_NOT_RECRUITING
AML
Institute of Hematology & Blood Diseases Hospital, China
 2025-01-21 PHASE2
NCT06744504 RECRUITING
AML; RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
 2025-01-10 PHASE3
NCT06497062 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia
Shanghai Jiao Tong University School of Medicine
 2024-10-30 PHASE2
NCT03214562 RECRUITING
High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
 2017-09-26 PHASE1; PHASE2
NCT07132684 RECRUITING
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China
 2025-08-31 PHASE3
NCT07046078 RECRUITING
Acute Leukemia of Ambiguous Lineage; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
 2025-09-26 PHASE2
NCT04190550 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
National Cancer Institute (NCI)
 2021-02-04 PHASE1
NCT04375631 RECRUITING
Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome; Refractory Acute Leukemia of Ambiguous Lineage; Refractory Acute Undifferentiated Leukemia
Fred Hutchinson Cancer Center
 2020-12-03 PHASE1
NCT04801797 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia
Massachusetts General Hospital
 2021-05-20 PHASE2
NCT07486479 NOT_YET_RECRUITING
Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
 2026-03-10 PHASE3
NCT07561892 RECRUITING
Acute Myeloid Leukemia; Newly Diagnosed; Chemotherapy Effect
Fujian Medical University Union Hospital
 2022-04-01 PHASE4
NCT03330821 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Therapy-Related Acute Myeloid Leukemia
University of Southern California
 2018-04-18 PHASE1; PHASE2
NCT05955261 SUSPENDED
Acute Myeloid Leukemia
St. Jude Children's Research Hospital
 2023-07-25 PHASE2
NCT06001788 RECRUITING
AML; AML With Mutated NPM1; Hematologic Malignancy; KMT2Ar; NPM1 Mutation; MLL Rearrangement; Leukemia; Acute Myeloid Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Acute Leukemia; Neoplasms by Histologic Type
Kura Oncology, Inc.
 2024-02-22 PHASE1
NCT05453903 ACTIVE_NOT_RECRUITING
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
 2022-10-04 PHASE1
NCT03117751 ACTIVE_NOT_RECRUITING
Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
 2017-03-29 PHASE2; PHASE3
NCT06114082 COMPLETED
Hepatocellular Carcinoma; Liver Cancer
Seoul National University Hospital
 2023-07-28 PHASE2
NCT06034470 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm
Fred Hutchinson Cancer Center
 2023-12-18 PHASE1
NCT03250338 COMPLETED
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc.
 2018-08-16 PHASE3
NCT06050941 NOT_YET_RECRUITING
Acute Myeloid Leukemia; Myelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University
 2024-04-02 PHASE2
NCT05313958 UNKNOWN
Leukemia, Monocytic, Acute; Pediatric AML
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
 2021-12-01 PHASE2; PHASE3
NCT06316960 RECRUITING
AML, Childhood; Relapse/Recurrence; Refractory AML; Core Binding Factor Acute Myeloid Leukemia; C-KIT Mutation
Children's Hospital of Soochow University
 2024-03-01 PHASE2
NCT03926624 TERMINATED
Leukemia, Myeloid, Acute
Delta-Fly Pharma, Inc.
 2019-11-22 PHASE3
NCT03164057 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Myelodysplastic Syndromes
St. Jude Children's Research Hospital
 2017-06-15 PHASE2
NCT04968015 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia
French Innovative Leukemia Organisation
 2022-05-25 PHASE2
NCT02416388 RECRUITING
Acute Myeloid Leukemia (AML)
University Hospital, Angers
 2015-01 PHASE2; PHASE3
NCT03455504 COMPLETED
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2018-10-26 PHASE2
NCT05697510 UNKNOWN
Acute Myeloid Leukemia (AML)
Nantes University Hospital
 2023-03-16 PHASE1
NCT03727633 TERMINATED
Carcinoma, Hepatocellular
University Hospital, Montpellier
 2018-07-19 PHASE2
NCT05518383 RECRUITING
Non-hodgkin Lymphoma,B Cell; Burkitt Lymphoma; Primary Mediastinal Lymphoma; Primary CNS Lymphoma; Diffuse Large B-cell Lymphoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
 2022-05-25 PHASE4
NCT04676243 WITHDRAWN
Acute Myeloid Leukemia
University Hospital Heidelberg
 2022-05 PHASE3
NCT01518556 COMPLETED
Leukemia, Myeloid, Acute
Konkuk University Medical Center
 2011-07 PHASE1; PHASE2
NCT02688140 COMPLETED
Acute Promyelocytic Leukemia
Technische Universität Dresden
 2016-06 PHASE3
NCT02881086 COMPLETED
Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Goethe University
 2016-08 PHASE3
NCT04214249 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2021-02-17 PHASE2
NCT04107727 COMPLETED
Acute Myeloid Leukemia
PETHEMA Foundation
 2019-09-05 PHASE2
NCT04778397 TERMINATED
Acute Myeloid Leukemia
Gilead Sciences
 2021-07-01 PHASE3
NCT03226418 COMPLETED
Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
University of Nebraska
 2017-07-07 PHASE2
NCT05177731 ACTIVE_NOT_RECRUITING
AML, Adult; Chemotherapy Effect
Chen Suning
 2022-03-01 PHASE3
NCT02013648 COMPLETED
Acute Myeloid Leukemia (AML)
University of Ulm
 2014-07 PHASE3
NCT04112589 UNKNOWN
Acute Myeloid Leukemia
PETHEMA Foundation
 2019-12-26 PHASE1; PHASE2
NCT05280444 UNKNOWN
Hepatocellular Carcinoma
Zhongda Hospital
 2022-05-28 PHASE2; PHASE3
NCT04547062 COMPLETED
Acute Myeloid Leukemia (AML)
Nantes University Hospital
 2020-12-29 PHASE1
NCT05697510 Recruiting
Acute Myeloid Leukemia (AML)
Nantes University Hospital
 2023-03-16 Phase 1
NCT02135874 COMPLETED
Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Leukemia of Ambiguous Lineage; Acute Undifferentiated Leukemia; Mixed Phenotype Acute Leukemia; Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified; Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified; Recurrent Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
 2014-10-27 PHASE2
NCT03599960 UNKNOWN
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Centre Hospitalier Universitaire de Besancon
 2019-05-02 PHASE2
NCT05053425 UNKNOWN
Acute Myeloid Leukemia
LanZhou University
 2021-10-20
NCT00534469 COMPLETED
Leukemia
City of Hope Medical Center
 2000-02-08 PHASE2
NCT01366898 UNKNOWN
Acute Lymphoblastic Leukemia
PETHEMA Foundation
 2007-06-30 PHASE4
NCT05053386 UNKNOWN
Hepatocellular Carcinoma
Zhejiang Cancer Hospital
 2021-10
NCT03860844 TERMINATED
Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia
Sanofi
 2019-08-06 PHASE2
NCT05404516 UNKNOWN
Core Binding Factor Acute Myeloid Leukemia
Nanfang Hospital, Southern Medical University
 2020-01-01 PHASE2
NCT04687098 COMPLETED
Leukemia, Myeloid, Acute
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
 2012-02-01 PHASE2
NCT00876031 COMPLETED
Soft Tissue Sarcoma
University Hospital Tuebingen
 2009-07-01 PHASE3
NCT04216771 UNKNOWN
AML in Remission
Fujian Medical University
 2020-01 PHASE2; PHASE3
NCT04250051 TERMINATED
Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome; Newly Diagnosed Acute Myeloid Leukemia (AML); IDH1 Mutation Myeloid Neoplasms; Acute Myeloid Leukemia (AML)
Northwestern University
 2020-12-21 PHASE1
NCT02020161 UNKNOWN
APL
PETHEMA Foundation
 2012-06 PHASE4
NCT01296178 UNKNOWN
Acute Myeloblastic Leukemia
PETHEMA Foundation
 2010-12
NCT04069208 UNKNOWN
Acute Myeloid Leukemia
Peking Union Medical College Hospital
 2019-09-03 PHASE2
NCT02310321 COMPLETED
Acute Myeloid Leukemia; FLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Inc
 2015-02-26 PHASE1; PHASE2
NCT02236013 COMPLETED
Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc.
 2015-01-07 PHASE1
NCT04178642 WITHDRAWN
Hepatocellular Carcinoma
University Hospital, Montpellier
 2020-09-22 PHASE2
NCT03379727 COMPLETED
Acute Myeloid Leukemia
Novartis Pharmaceuticals
 2018-02-13 PHASE3
NCT02703272 TERMINATED
Lymphoma, Non-Hodgkin
Janssen Research & Development, LLC
 2016-07-01 PHASE3
NCT04087967 UNKNOWN
Acute Myeloid Leukemia; Induction Chemotherapy
The First Affiliated Hospital of Soochow University
 2019-04-01 PHASE3
NCT03564704 UNKNOWN
Leukemia; Leukemia, Acute; Adult Lymphoblastic Lymphoma; Leukemia, Lymphoblastic; Leukemia, T Cell; Adult Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
 2016-02-14 PHASE2; PHASE3
NCT02473146 COMPLETED
Acute Myeloid Leukemia
Versailles Hospital
 2015-11-18 PHASE2; PHASE3
NCT03512197 COMPLETED
Acute Myeloid Leukemia (AML)
Novartis Pharmaceuticals
 2018-07-20 PHASE3
NCT01064557 UNKNOWN
Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 1993-10
NCT02848183 UNKNOWN
Pediatric Acute Myeloid Leukemia
Samsung Medical Center
 2016-01 PHASE2
NCT02096055 COMPLETED
Untreated Adult Acute Myeloid Leukemia
M.D. Anderson Cancer Center
 2014-04-04 PHASE2
NCT03390387 UNKNOWN
Childhood Acute Lymphoblastic Leukemia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
 2015-11
NCT02339740 ACTIVE_NOT_RECRUITING
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Children's Oncology Group
 2015-07-21 PHASE3
NCT03194932 COMPLETED
Acute Myeloid Leukemia
St. Jude Children's Research Hospital
 2017-07-11 PHASE1
NCT02441803 COMPLETED
Leukemia
M.D. Anderson Cancer Center
 2015-09-14 PHASE2
NCT02400281 COMPLETED
Acute Myeloid Leukemia
Arog Pharmaceuticals, Inc.
 2015-09 PHASE1; PHASE2
NCT03553238 UNKNOWN
Leukemia, Acute; Leukemia, T Cell; Leukemia, Lymphoblastic
Nanfang Hospital, Southern Medical University
 2016-02-14 PHASE2; PHASE3
NCT02029950 COMPLETED
Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia-2; High Risk Myelodysplastic Syndrome; Myeloproliferative Neoplasm
National Cancer Institute (NCI)
 2013-12-16 PHASE1
NCT02464657 COMPLETED
Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome
M.D. Anderson Cancer Center
 2015-07 PHASE1; PHASE2
NCT02937662 COMPLETED
Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
 2016-10 PHASE2
NCT01822015 COMPLETED
Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Untreated Adult Acute Myeloid Leukemia
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
 2013-03-15 EARLY_PHASE1
NCT02283177 COMPLETED
Newly Diagnosed AML With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc.
 2015-01 PHASE2
NCT02835729 COMPLETED
Acute Myeloid Leukemia
NewLink Genetics Corporation
 2016-07 PHASE1
NCT03444649 WITHDRAWN
AML
Insel Gruppe AG, University Hospital Bern
 2018-09 PHASE1
NCT02652871 COMPLETED
Leukemia
M.D. Anderson Cancer Center
 2016-05-09 PHASE1
NCT03661515 COMPLETED
Acute Myeloid Leukemia
PETHEMA Foundation
 2018-07-17 PHASE1
NCT02873338 COMPLETED
Acute Myeloid Leukemia
Jazz Pharmaceuticals
 2016-08 PHASE2
NCT02671708 COMPLETED
Autologous Hematopoietic Stem Cell Transplantation; Acute Myeloid Leukemia; Conditioning
Nanfang Hospital, Southern Medical University
 2016-01 PHASE2; PHASE3
NCT02632708 ACTIVE_NOT_RECRUITING
Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS); AML Arising From Antecedent Hematologic Disorder (AHD); AML Arising After Exposure to Genotoxic Injury
Institut de Recherches Internationales Servier
 2015-12-31 PHASE1
NCT00840177 COMPLETED
Leukemia
SWOG Cancer Research Network
 2009-12-10 PHASE2
NCT02440568 TERMINATED
Acute Myeloid Leukemia
University of Illinois at Chicago
 2015-06-05 PHASE1; PHASE2
NCT02421939 COMPLETED
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc.
 2015-10-20 PHASE3
NCT02249091 COMPLETED
Acute Myeloid Leukemia (Relapsed/Refractory)
GSO Global Clinical Research BV
 2014-09 PHASE2
NCT01342692 UNKNOWN
MDS
Assistance Publique - Hôpitaux de Paris
 2011-06 PHASE2
NCT02527174 WITHDRAWN
Leukemia, Myeloid, Acute; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute
University of Alberta
 2016-11 PHASE1
NCT01876953 TERMINATED
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
City of Hope Medical Center
 2013-09-13 PHASE1; PHASE2
NCT02779283 COMPLETED
Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia
OHSU Knight Cancer Institute
 2016-01-13 PHASE1
NCT02626338 COMPLETED
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Arog Pharmaceuticals, Inc.
 2016-02 PHASE1; PHASE2
NCT01794702 COMPLETED
Leukemia
M.D. Anderson Cancer Center
 2013-02-20 PHASE1; PHASE2
NCT02680951 WITHDRAWN
Acute Myeloid Leukemia
Emory University
 2015-12 PHASE1
NCT02306291 COMPLETED
Leukemia, Myeloid, Acute
GlycoMimetics Incorporated
 2015-03 PHASE1; PHASE2
NCT02834390 COMPLETED
Acute Myeloid Leukemia
Daiichi Sankyo Co., Ltd.
 2016-08-12 PHASE1
NCT02560025 COMPLETED
Acute Myeloid Leukemia
Massachusetts General Hospital
 2015-12 PHASE2
NCT02185768 COMPLETED
Liver Cancer
Federation Francophone de Cancerologie Digestive
 2015-01 PHASE2
NCT01484171 UNKNOWN
Acute Myeloid Leukemia
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
 2011-08 PHASE3
NCT02635074 TERMINATED
Recurrent Adult Acute Myeloid Leukemia
Steven E. Coutre
 2016-11 PHASE1
NCT01289457 COMPLETED
Leukemia
M.D. Anderson Cancer Center
 2011-02-02 PHASE1; PHASE2
NCT02046122 COMPLETED
Acute Myeloid Leukemia; Myelodysplastic Syndrome
Duke University
 2014-07 PHASE1; PHASE2
NCT01802333 COMPLETED
Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2013-02-12 PHASE3
NCT01692197 COMPLETED
Leukemia
M.D. Anderson Cancer Center
 2013-02-01 PHASE2
NCT02277847 UNKNOWN
Acute Myeloid Leukemia
Guangdong Provincial People's Hospital
 2010-03 PHASE4
NCT02905994 WITHDRAWN
AML
Massachusetts General Hospital
 2016-09 PHASE1
NCT00422591 COMPLETED
Leukemia; Acute Myeloid Leukemia; AML
M.D. Anderson Cancer Center
 2006-12 PHASE2
NCT01958996 COMPLETED
High Grade Lymphomas CD20 Positive
Poitiers University Hospital
 2009-01 PHASE1; PHASE2
NCT01698879 COMPLETED
Novo Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
 2009-10 PHASE2
NCT01773408 COMPLETED
Myelogenous Leukemia, Acute
Hoffmann-La Roche
 2013-02 PHASE1
NCT00840346 COMPLETED
Acute Myeloblastic Leukaemia
PETHEMA Foundation
 2009-09 PHASE1; PHASE2
NCT01435343 COMPLETED
Acute Myeloblastic Leukemia
PETHEMA Foundation
 2012-07 PHASE1; PHASE2
NCT02652871 Completed
Leukemia
M.D. Anderson Cancer Center|Eli Lilly and Company|High Impact Clinical Research Support Program
 2016-05-09 Phase 1
NCT02144675 COMPLETED
Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Rutgers, The State University of New Jersey
 2009-01 PHASE2
NCT01067274 WITHDRAWN
Acute Myeloid Leukemia
Acute Leukemia French Association
 2010-04 PHASE3
NCT00413166 COMPLETED
Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
 2006-12 PHASE2
NCT01766375 UNKNOWN
Acute Myeloid Leukemia
Guangxi Medical University
 2012-08 PHASE3
NCT01873807 UNKNOWN
Acute Lymphoblastic Leukemia
Nanfang Hospital, Southern Medical University
 2013-05 PHASE4
NCT00528398 COMPLETED
Leukemia
City of Hope Medical Center
 1994-09 PHASE2
NCT02028949 COMPLETED
Unresectable Non-metastatic Hepatocellular Carcinoma; Child A/B7 Cirrhosis
Centre Hospitalier Universitaire Dijon
 2012-11-22 PHASE1
NCT01779843 COMPLETED
Acute Myelogenous Leukemia
Massachusetts General Hospital
 2013-04 PHASE1
NCT00866918 COMPLETED
Childhood Acute Promyelocytic Leukemia With PML-RARA; Myeloid Neoplasm
Children's Oncology Group
 2009-03-09 PHASE3
NCT00831766 COMPLETED
Myelodysplastic Syndrome; Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
 2009-06-25 PHASE1; PHASE2
NCT02049801 TERMINATED
Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
Bruno C. Medeiros
 2014-12 PHASE1
NCT01831232 COMPLETED
Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
 2013-05
NCT01990807 UNKNOWN
Childhood Acute Lymphoblastic Leukemia; Philadelphia Chromosome, Ph^1^, Absent; B-cell Childhood Acute Lymphoblastic Leukemia
Chinese Academy of Medical Sciences
 2012-10 PHASE4
NCT01242774 COMPLETED
Acute Myeloid Leukemia (AML)
Novartis Pharmaceuticals
 2010-10 PHASE1
NCT00907582 TERMINATED
Acute Promyelocytic Leukemia; Relapse
Shanghai Jiao Tong University School of Medicine
 2009-06 PHASE2
NCT00458848 COMPLETED
Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2004-10 PHASE2
NCT00317408 UNKNOWN
Lymphoma
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
 2004-04
NCT00656617 COMPLETED
Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
 2008-04 PHASE2
NCT01132586 COMPLETED
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Alkylating Agent-Related Acute Myeloid Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2010-05 PHASE1
NCT01700413 COMPLETED
Di Novo Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
 2012-10 PHASE2
NCT01607645 TERMINATED
Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts
Fred Hutchinson Cancer Center
 2012-07 PHASE2
NCT00067028 COMPLETED
Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
 2003-12 PHASE2
NCT01154439 COMPLETED
Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2010-10 PHASE1
NCT01035502 COMPLETED
Acute Myeloid Leukemia
Clavis Pharma
 2009-12 PHASE2
NCT01534702 UNKNOWN
Acute Myeloid Leukemia
Hannover Medical School
 2012-01 PHASE1; PHASE2
NCT01025154 COMPLETED
Acute Myeloid Leukemia
M.D. Anderson Cancer Center
 2010-01 PHASE2
NCT00666588 COMPLETED
Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myelomonocytic Leukemia (M4); Childhood Acute Basophilic Leukemia; Childhood Acute Eosinophilic Leukemia; Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2008-04 PHASE2
NCT00590837 COMPLETED
Acute Myeloid Leukemia
University Hospital, Bordeaux
 2008-02 PHASE3
NCT00838240 UNKNOWN
Leukemia; Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC
 2008-11 PHASE1; PHASE2
NCT01141725 COMPLETED
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Untreated Adult Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
 2010-09 PHASE1; PHASE2
NCT00180128 UNKNOWN
Leukemia, Promyelocytic, Acute
Technische Universität Dresden
 2000-01 PHASE4
NCT00482833 COMPLETED
Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2007-08 PHASE3
NCT01180322 COMPLETED
Acute Myeloid Leukemia (AML)
University of Ulm
 2010-11 PHASE2
NCT02870010 COMPLETED
Localized Non-Resectable Adult Hepatocellular Carcinoma
Centre Hospitalier Universitaire Dijon
 2010-02 PHASE1
NCT00408278 COMPLETED
Acute Promyelocytic Leukemia
PETHEMA Foundation
 2005-07 PHASE4
NCT01145846 UNKNOWN
Acute Myelogenous Leukemia
Cooperative Study Group A for Hematology
 2010-05 PHASE3
NCT00967512 WITHDRAWN
Acute Myelogenous Leukemia
Eleos, Inc.
 2012-01 PHASE2
NCT01040559 COMPLETED
Carcinoma, Hepatocellular
Centre Hospitalier Universitaire Dijon
 2009-12 PHASE1
NCT00151242 COMPLETED
Acute Myeloid Leukemia
University of Ulm
 2004-07 PHASE2; PHASE3
NCT00198991 COMPLETED
Adult Acute Lymphocytic Leukemia
Goethe University
 2003-04 PHASE4
NCT01305135 COMPLETED
High Grade Myelodysplastic Syndrome Lesions
Groupe Francophone des Myelodysplasies
 2010-12-30 PHASE1; PHASE2
NCT00198978 COMPLETED
Adult Acute Lymphocytic Leukemia
Goethe University
 2003-01 PHASE4
NCT00542971 COMPLETED
AML; Acute Myeloid Leukemia; Myelodysplastic Disorders
M.D. Anderson Cancer Center
 2007-10 PHASE1; PHASE2
NCT00528450 TERMINATED
Leukemia
Memorial Sloan Kettering Cancer Center
 2007-09 PHASE2
NCT00126321 UNKNOWN
Leukemia, Myelocytic, Acute
University Hospital, Bonn
 2004-11 PHASE2
NCT01018069 TERMINATED
Leukemia
Aegera Therapeutics
 2009-11 PHASE2
NCT00210366 TERMINATED
Lymphoma, B-Cell
International Extranodal Lymphoma Study Group (IELSG)
 2004-11 PHASE2
NCT00124813 UNKNOWN
Multiple Myeloma
University Hospital, Bonn
 2002-08 PHASE2
NCT00002517 COMPLETED
Leukemia; Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC
 1993-03 PHASE3
NCT00469859 COMPLETED
Leukemia
Children's Oncology Group
 2007-06 PHASE1; PHASE2
NCT00331513 COMPLETED
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Blastic Phase Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
National Cancer Institute (NCI)
 2006-03 PHASE1
NCT00967057 COMPLETED
Leukemia
Children's Cancer and Leukaemia Group
 2002-10 PHASE3
NCT00620321 COMPLETED
Acute Myeloid Leukemia
Eli Lilly and Company
 2008-03 PHASE2
NCT00093483 COMPLETED
Leukemia
Roswell Park Cancer Institute
 2002-04 PHASE1
NCT01247493 COMPLETED
Acute Myeloid Leukemia
Seoul National University Hospital
 2007-06 PHASE2
NCT00151255 COMPLETED
Acute Myeloid Leukemia
University of Ulm
 2004-06 PHASE3
NCT00878722 COMPLETED
Acute Myeloid Leukemia
Valerio Therapeutics
 2007-08 PHASE1; PHASE2
NCT00464217 COMPLETED
Acute Myeloblastic Leukaemia
PETHEMA Foundation
 1998-10 PHASE4
NCT00382954 COMPLETED
Acute Myelogenous Leukemia
University of Kentucky
 2004-02 PHASE1
NCT00193973 COMPLETED
Primary Central Nervous System Lymphoma
Trans Tasman Radiation Oncology Group
 2001-07 PHASE2
NCT00052299 COMPLETED
Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
 2002-09 PHASE3
NCT00465933 COMPLETED
Acute Promyelocytic Leukemia
PETHEMA Foundation
 1999-03 PHASE4
NCT00487448 COMPLETED
Myelodysplastic Syndrome; Acute Myeloblastic Leukemia
PETHEMA Foundation
 1998-07 PHASE4
NCT00074737 COMPLETED
Acute Myelogenous Leukemia
Eleos, Inc.
 2004-04 PHASE2
NCT00016159 COMPLETED
Leukemia
Memorial Sloan Kettering Cancer Center
 2000-11 PHASE2
NCT00002565 COMPLETED
Lymphoma
M.D. Anderson Cancer Center
 1994-05-25 PHASE3
NCT00002761 WITHDRAWN
Leukemia
Columbia University
 1996-02 PHASE1; PHASE2
NCT00096148 TERMINATED
Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Basophilic Leukemia; Childhood Acute Eosinophilic Leukemia; Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
National Cancer Institute (NCI)
 2004-10 PHASE2
NCT00077116 COMPLETED
Leukemia; Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC
 2003-11 PHASE2
NCT00096122 COMPLETED
Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2004-09 PHASE1; PHASE2
NCT00002798 COMPLETED
Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Secondary Myelodysplastic Syndromes; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
National Cancer Institute (NCI)
 1996-08 PHASE3
NCT00002812 COMPLETED
Leukemia
Children's Oncology Group
 1996-09 PHASE3
NCT00086099 COMPLETED
Leukemia; Acute Myeloid Leukemia
MedImmune LLC
 2004-07 PHASE1; PHASE2
NCT00505700 COMPLETED
Leukemia
Massachusetts General Hospital
 2003-07 PHASE1
NCT00146120 COMPLETED
Acute Myeloid Leukemia
University of Ulm
 1998-05 PHASE3
NCT00003178 COMPLETED
Leukemia
Children's Oncology Group
 1998-03 PHASE2
NCT00023920 TERMINATED
Blastic Phase Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive
National Cancer Institute (NCI)
 2001-07 PHASE2
NCT00002868 COMPLETED
Leukemia
Eastern Cooperative Oncology Group
 1997-11-20 PHASE3
NCT00002835 COMPLETED
Lymphoma
M.D. Anderson Cancer Center
 1995-10-30 PHASE3
NCT00187083 COMPLETED
Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
 1997-02 PHASE3
NCT00199056 COMPLETED
Adult Acute Lymphocytic Leukemia
Goethe University
 1999-10 PHASE4
NCT00199095 COMPLETED
Adult Acute Lymphocytic Leukemia
Goethe University
 1997-02 PHASE4
NCT00002800 COMPLETED
Leukemia; Myelodysplastic Syndromes; Neutropenia
Memorial Sloan Kettering Cancer Center
 1996-07 PHASE2
NCT00002609 COMPLETED
Leukemia
Memorial Sloan Kettering Cancer Center
 1994-08 PHASE2
NCT00003783 COMPLETED
Leukemia
Children's Oncology Group
 1999-03 PHASE2
NCT00002816 COMPLETED
Leukemia
Children's Oncology Group
 1996-12 PHASE3
NCT00187005 TERMINATED
Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
 1998-07 PHASE3
NCT00003729 TERMINATED
Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
 1998-12 PHASE2
NCT00002833 COMPLETED
Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes
M.D. Anderson Cancer Center
 1994-10 PHASE2
NCT00006122 COMPLETED
Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
 2000-06 PHASE2
NCT00002719 COMPLETED
Leukemia; Neutropenia
European Organisation for Research and Treatment of Cancer - EORTC
 1995-12 PHASE3
NCT00002945 COMPLETED
Leukemia
Roswell Park Cancer Institute
 1996-12 PHASE3
NCT00003405 WITHDRAWN
Leukemia
Rush University Medical Center
 1998-04 PHASE2
NCT00003603 UNKNOWN
Multiple Myeloma and Plasma Cell Neoplasm
Riverside Haematology Group
 1998-03 PHASE3
NCT00003639 UNKNOWN
Lymphoma
Scotland and Newcastle Lymphoma Group
 1993-11 PHASE3
NCT00003758 UNKNOWN
Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
 1998-12 PHASE2
NCT00480064 COMPLETED
Acute Myeloid Leukemia
French Innovative Leukemia Organisation
 1995-07 PHASE3
NCT00209833 UNKNOWN
De Novo Akute Myeloid Leukemia (AML); Secondary Acute Myeloid Leukemia (AML); Refractory Anemia With Excess of Blasts in Transformation
Hannover Medical School
 1999-01 PHASE2; PHASE3
NCT00004905 COMPLETED
Leukemia
Loyola University
 1999-10 PHASE2
NCT00002989 UNKNOWN
Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC
 1997-03 PHASE3
NCT00002549 UNKNOWN
Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
 1993-11 PHASE3
NCT00363025 TERMINATED
Acute Myeloid Leukemia
Acute Leukemia French Association
 1999-11 PHASE3
NCT00004878 WITHDRAWN
Graft Versus Host Disease; Leukemia
Jonsson Comprehensive Cancer Center
 PHASE2
NCT00005823 COMPLETED
Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Leukemia Research Fund
 1998-12 PHASE3
NCT00002701 UNKNOWN
Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
 1995-10 PHASE3
NCT01039363 UNKNOWN
Acute Myeloid Leukemia
Samsung Medical Center
 PHASE2
NCT00002658 UNKNOWN
Leukemia; Neutropenia
Medical Research Council
 1994-01 PHASE3
NCT00002926 UNKNOWN
Leukemia; Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC
 1996-12 PHASE3
NCT00559221 UNKNOWN
Acute Myeloid Leukemia
Cooperative Study Group A for Hematology
 2004-12 PHASE2
NCT00199147 UNKNOWN
Acute Myeloid Leukemia
Johann Wolfgang Goethe University Hospital
 2000-01 PHASE4
NCT00002771 UNKNOWN
Leukemia
German CML Study Group
 1995-01 PHASE3
NCT00025402 UNKNOWN
Leukemia
III. Medizinische Klinik Mannheim
 1997-07 PHASE3
NCT00003602 UNKNOWN
Leukemia; Myelodysplastic Syndromes
Riverside Haematology Group
 1998-03 PHASE3
NCT00003268 COMPLETED
Drug/Agent Toxicity by Tissue/Organ; Leukemia
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
 1998-01 PHASE1
NCT00002532 UNKNOWN
Leukemia
Hannover Medical School
 1993-01 PHASE2
NCT00006232 COMPLETED
Multiple Myeloma and Plasma Cell Neoplasm
West of Scotland Lymphoma Group
 1996-10 PHASE3
NCT00107523 COMPLETED
Leukemia
Fred Hutchinson Cancer Center
 2005-01 PHASE1
NCT00199186 UNKNOWN
Philadelphia Positive Acute Lymphoblastic Leukemia; Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Johann Wolfgang Goethe University Hospital
 2002-03 PHASE2
NCT00006367 COMPLETED
Chronic Myeloproliferative Disorders
Fred Hutchinson Cancer Center
 2000-05 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-03)

Check the Idarubicin HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Idarubicin intercalates into DNA and inhibits topoisomerase II, leading to the formation of DNA-protein cleavable complexes and the suppression of DNA synthesis. This molecular blockade triggers cytotoxic autophagy and marked cellular antiproliferative activity, directly underlying its therapeutic application in treating hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.